A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.

Zhao, Hongli; Sun, Guoxun; Kong, Desheng; Zhang, Yujing; Shi, Wudan; Zhao, Mingming; Hong, Luojia; Qiao, Zhenkui

Zhao, Hongli; Sun, Guoxun; Kong, Desheng; Zhang, Yujing; Shi, Wudan; Zhao, Mingming; Hong, Luojia; Qiao, Zhenkui.

Affiliation

Zhao H; Department of Hematology, Fourth Affiliated Hospital of Harbin Medical University, No. 37 Yiyuan Street, Nangang District, Harbin, 150081, Heilongjiang Province, China.

Med Oncol ; 32(3): 79, 2015 Mar.

Article in En | MEDLINE | ID: mdl-25698531

Subject(s)

Antineoplastic Agents/therapeutic use; Arsenicals/therapeutic use; Lymphoma/drug therapy; Lymphoma/mortality; Oxides/therapeutic use; Adult; Aged; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/adverse effects; Arsenic Trioxide; Arsenicals/administration & dosage; Arsenicals/adverse effects; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymphoma/pathology; Male; Middle Aged; Oxides/administration & dosage; Oxides/adverse effects; Recurrence; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxides / Arsenicals / Lymphoma / Antineoplastic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Med Oncol Journal subject: NEOPLASIAS Year: 2015 Document type: Article Affiliation country: China

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google